debt_leverage_profile
Early-stage biotech/enzyme company; likely minimal debt, equity-funded; 20% rate rise immaterial given negligible interest-bearing liabilities
Inferred
Agent_Inference
interest_rate_sensitivity
Low sensitivity; pre-revenue or early-revenue stage reliant on equity capital, not debt financing; rate hikes compress valuation multiples more than cash costs
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Specialty fermentation substrate sourcing (China-dominant) and rare cofactor/reagent supply via European chemical hubs (Rotterdam/Hamburg chokepoints)
Inferred
Agent_Inference
international_expansion_readiness
Limited international revenue; USD-denominated contracts likely standard; minimal sovereign currency devaluation exposure at current scale
Inferred
Agent_Inference
geographic_footprint
Primarily US-based operations; early-stage international presence modest; currency risk low but EUR and CNY exposure possible via supply chain
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency likely on single fermentation/bioreactor contract manufacturer and proprietary enzyme substrate suppliers; substitution timeline 6–18 months
Inferred
Agent_Inference
business_model_type_primary
Cloud termination highly disruptive; computational enzyme design and bioinformatics pipelines likely AWS/GCP-dependent; 30-day migration technically infeasible
Inferred
Agent_Inference
business_model_type_secondary
B2B SaaS/licensing hybrid; enzyme IP licensing combined with contract R&D services for pharma, food, and industrial biotech customers
Inferred
Agent_Inference
switching_cost_profile
Moderate-to-high API coupling risk if proprietary enzyme design platform is embedded in customer R&D workflows; switching requires revalidation cycles
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model based on IP licensing and R&D services, not token/investment schemes; no securities classification expected
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR exposure if EU pharma partners share proprietary compound data; CCPA risk low given B2B focus and limited consumer data handling
Inferred
Agent_Inference
antitrust_exposure_flag
Low current antitrust risk; niche enzyme IP market; risk rises if platform achieves dominant position in industrial enzyme licensing segment
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Estimated 40–60% recurring (licensing, retainer R&D agreements), 40–60% transactional (milestone payments, custom enzyme development contracts)
Inferred
Agent_Inference
monetization_vector
IP licensing fees, milestone-based R&D contracts, and potential royalty streams from commercialized enzyme applications in pharma/food/industrial sectors
Inferred
Agent_Inference
pricing_architecture
Value-based pricing on IP licensing; cost-plus on contract R&D; vulnerable to margin compression if large pharma customers demand exclusivity discounts
Inferred
Agent_Inference
pricing_power_rating
Moderate; proprietary enzyme IP provides differentiation but pharma buyers have negotiating leverage; rating 6/10
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margin 60–75% on licensing revenue; blended margin 45–60% when contract R&D services included
Inferred
Agent_Inference
churn_vulnerability_index
Low free-rider risk given IP protection; churn risk moderate if enzyme performance benchmarks not met in customer validation phases
Inferred
Agent_Inference
headcount_cost_structure
Sublinear growth possible via IP licensing scale; R&D services revenue remains headcount-linear; hybrid model requires selective scientist hiring at scale
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of licensing revenue near-zero at scale; contract R&D services carry high marginal cost; platform IP is primary leverage asset
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely decreases via reputation effects in pharma/biotech; LTV:CAC ratio should improve to 5:1+ if licensing mix increases
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; indirect data network effect possible if enzyme performance dataset grows with deployments, improving AI design models
Inferred
Agent_Inference
asset_efficiency_ratio
-155.1% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Tier 3 (moderate vulnerability); pharma R&D budgets relatively resilient but industrial biotech and food sector clients cut discretionary enzyme R&D in downturns
Inferred
Agent_Inference
customer_segment_primary
Large pharma and specialty chemical companies seeking enzymatic synthesis solutions; top-3 customers likely represent 50–70% of revenue
Inferred
Agent_Inference
customer_segment_secondary
Food & beverage manufacturers and agricultural biotech firms seeking enzyme optimization for processing efficiency and sustainability compliance
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
242.5% CapEx / Revenue (High-CapEx Infrastructure)
High
SEC-XBRL
sec_cik
0002010788
High
SEC-EDGAR
ticker
EXOZ
High
SEC-EDGAR